Quiet Therapeutics is a pioneering biotech company founded in 2009 that focuses on advancing a revolutionary nanoparticle-based delivery system, known as gagomers, to target oncology and inflammation. By leveraging the unique targeting capabilities of their groundbreaking technology, the company aims to expand the range of drug targets in cancer and inflammation. This innovative delivery method enables them to access cell components that are typically inaccessible by traditional therapeutic agents like small molecules or antibodies.
The company received a $12.00M Series A investment on April 12, 2015 from Jerusalem Global Ventures. Quiet Therapeutics operates within the Biotechnology and Information Technology industries, positioning itself as a promising player in the intersection of technology and life sciences.
Quiet Therapeutics' mission to revolutionize cancer and inflammation treatments through unmatched precision and versatility signifies a strong potential for growth and impact, making it an appealing investment opportunity for venture capitalists seeking innovative solutions in the biotechnology space. With continued support and strategic partnerships, Quiet Therapeutics is well-positioned for significant advancements and contributions to the healthcare industry.
